Evidence map›Paper›PMID 36632072›Full record

ReviewSaudi journal of biological sciences2023

l-carnitine: Nutrition, pathology, and health benefits.

Abdulaziz Hassan Alhasaniah

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Saudi journal of biological sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 47 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
47citing papers in PubMed, 4 pooled it
11.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

47 citing papers in PubMed, 4 syntheses or guidelines pooled it, 89 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Linking Brain Morphometry to Psychometric Measures and Energy-Metabolic Biomarkers in Adults With Autism Spectrum Disorder.Autism research : official journal of the International Society for Autism Research · 2026
    Article
  9. Article
  10. Review
  11. Article
  12. Insulin Resistance and Inflammation.International journal of molecular sciences · 2026
    Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Abdulaziz Hassan AlhasaniahDepartment of Clinical Laboratory Sciences, Faculty of Applied Medical Sciences, Najran University, P.O. Box 1988, Najran 61441, Saudi Arabia.
Najran University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Carnitine is a medically needful nutrient that contributes in the production of energy and the metabolism of fatty acids. Bioavailability is higher in vegetarians than in people who eat meat. Deficits in carnitine transporters occur as a result of genetic mutations or in combination with other illnesses such like hepatic or renal disease. Carnitine deficit can arise in diseases such endocrine maladies, cardiomyopathy, diabetes, malnutrition, aging, sepsis, and cirrhosis due to abnormalities in carnitine regulation. The exogenously provided molecule is obviously useful in people with primary carnitine deficits, which can be life-threatening, and also some secondary deficiencies, including such organic acidurias: by eradicating hypotonia, muscle weakness, motor skills, and wasting are all improved l-carnitine (LC) have reported to improve myocardial functionality and metabolism in ischemic heart disease patients, as well as athletic performance in individuals with angina pectoris. Furthermore, although some intriguing data indicates that LC could be useful in a variety of conditions, including carnitine deficiency caused by long-term total parenteral supplementation or chronic hemodialysis, hyperlipidemias, and the prevention of anthracyclines and valproate-induced toxicity, such findings must be viewed with caution.

Indexed as

AD, Alzheimer's diseaseAIF, Apoptosis-inducing factorAnti-wasting effectBBB, Blood–brain barrierCC, Cancer cachexiaCHF, Chronic heart failureCOPD, Chronic obstructive pulmonary diseaseESRD, End-stage renal diseaseGOT, Glutamic oxaloacetic transaminaseHCC, Hepatocellular carcinomaHealth benefitsHFD, High-Fat DietHOI, Highest observed intakel-carnitineLC, l-carnitineMI, myocardial infarctionMTX, MethotrexateNF-kB, Nuclear factor-kBNutritionOSL, Observed safe levelPathologyPCD, Primary carnitine deficiencyROS, Reactive oxygen speciesSCD, Secondary carnitine deficiencyTLE, Temporal lobe epilepsyVD, Vascular dementia

Identifiers

PMID36632072
PMCPMC9827390
OpenAlexW4313367288

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.